Granata Bio Announces Strategic Investment and Collaboration with Gedeon Richter to Expand U.S. Fertility Market Leadership

BOSTON, May 13, 2025 /PRNewswire/ -- Granata Bio ("Granata"), a U.S.-based biotechnology company focused on advancing fertility therapeutics, today announced a strategic partnership with Gedeon Richter Plc. ("Richter"), a global leader in women's health. The agreement includes Richter's acquisition of a significant equity stake in Granata and the appointment of a Richter representative to Granata's Board of Directors.

Richter issued a press release today outlining the partnership and highlighting the strategic importance of the collaboration in expanding its presence in the United States and strengthening its Women's Health Care portfolio.

The partnership brings together two highly complementary organizations. Granata contributes deep U.S. market expertise, including strong relationships with key opinion leaders (KOLs), clinical development and regulatory strategy, and commercial execution. Richter offers global scale, proven manufacturing capabilities, and a long-standing commercial presence in reproductive health markets worldwide.

In addition to the equity investment, the companies have signed a binding term sheet for the co-development of BEMFOLA^®, Richter's recombinant follicle stimulating hormone (FSH) for the U.S. market, and a royalty purchase agreement for Granata's proprietary human menopausal gonadotropin (hMG) program, aligning long-term commercial interests in the fertility space.

"We're proud to partner with Gedeon Richter, an organization whose global footprint and manufacturing excellence perfectly complement Granata Bio's strengths in the U.S. market. This collaboration brings together the best of both companies: deep therapeutic expertise, operational agility, and a shared commitment to improving access to fertility care," said Evan Sussman, CEO and Co-Founder of Granata Bio.

Stephen Medeiros, Chief Operating Officer of Granata Bio, added, "FSH is the most prescribed gonadotropin by volume and represents a cornerstone of ovarian stimulation treatment. The addition of BEMFOLA^® to our pipeline significantly strengthens our portfolio, providing coverage across all major IVF product categories. Together, these assets position us to better support the evolving needs of patients and providers in the U.S. fertility landscape."

This partnership, coupled with the recent acquisition of Oviva Therapeutics, further solidifies Granata's leadership position in the fertility sector, as it continues to build a portfolio of innovative assets designed to improve outcomes and access for individuals seeking reproductive care.

About Granata Bio

Granata Bio is a U.S. based biopharmaceutical company committed to advancing innovation in women's health and infertility. Founded in 2018, the company's pipeline includes a range of fertility therapies, with collaborations spanning multiple drug classes to address unmet needs in reproductive medicine. Granata Bio is the parent company of Oviva Therapeutics, Inc., a wholly owned subsidiary developing first-in-class therapeutics aimed at preserving ovarian function and extending female health span. For more information, please visit www.granata.bio and LinkedIn. 

About Gedeon Richter Plc.

Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.7bn and sales of EUR 2.2bn in 2024, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com

SOURCE Granata Bio